Breast Lump Surgery (Lumpectomy & Excision Biopsy) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Breast lump surgery encompasses several distinct surgical procedures aimed at removing or sampling abnormal tissue from the breast. The most common procedures are excision biopsy (removal of a lump for histological diagnosis when core needle biopsy is inconclusive or technically not feasible), wide local excision/lumpectomy (removal of a confirmed or suspected malignant lump with a surrounding margin of normal tissue), and oncoplastic breast surgery (combining tumour removal with plastic surgical reconstruction techniques to preserve breast shape and volume).

Approximately 10–12% of women will present with a palpable breast lump during their lifetime; the majority are benign — fibroadenomas, cysts, fibrocystic change, and lipomas — but any new breast lump requires triple assessment: clinical examination, breast imaging (mammography and/or ultrasound), and core needle biopsy. Surgery is performed when histology confirms malignancy or when there is high clinical or radiological suspicion (BI-RADS 4–5) not adequately sampled by biopsy, or for symptomatic benign lumps the patient wishes removed.

Lumpectomy with adjuvant radiotherapy is the gold standard breast-conserving treatment for early invasive breast cancer, with 20-year survival data from landmark randomised trials (NSABP B-06, EORTC 10801) confirming equivalence to mastectomy for overall survival. Breast-conserving surgery is now possible in approximately 60–70% of early breast cancer patients in high-income countries, with oncoplastic techniques extending eligibility to patients with larger tumours relative to breast size. Wire-guided localisation, vacuum-assisted excision, and MRI-guided approaches allow removal of non-palpable lesions identified on imaging.

• Early invasive breast cancer (Stage I–II): Wide local excision (lumpectomy) with clear histological margins, followed by adjuvant whole-breast radiotherapy, is standard treatment for T1–T2 tumours with appropriate tumour-to-breast ratio. Sentinel lymph node biopsy is performed concurrently for axillary staging.
• Ductal carcinoma in situ (DCIS): Non-invasive breast cancer confined to the ductal system. Wide local excision with clear margins (minimum 2 mm for DCIS) is followed by whole-breast radiotherapy (reducing recurrence risk by 50%) in most cases. Low-grade, small, widely excised DCIS may be managed with excision alone in selected older patients.
• Symptomatic fibroadenoma: Benign breast lump most common in women aged 15–35. Excision is offered for enlarging, large (>3 cm), symptomatic, or patient-requested removal after biopsy confirmation of benign diagnosis. Small stable fibroadenomas with concordant biopsy can be managed by observation.
• Complex breast cyst: Cysts with internal debris, septations, or solid components (BI-RADS 3–4) that cannot be fully aspirated or are recurring after aspiration may require excision biopsy to exclude intraductal papillary carcinoma or intracystic carcinoma.
• Intraductal papilloma: Benign tumour within the breast ducts causing bloody nipple discharge; excision of the affected duct segment (microdochectomy) or the central duct complex (Hadfield's procedure for multiple ducts) provides diagnosis and treatment.
• Phyllodes tumour: Rare fibroepithelial tumour requiring wide excision with 1 cm margin due to risk of local recurrence; malignant phyllodes may require mastectomy.
• Non-palpable lesion requiring biopsy: Indeterminate lesions on mammography or MRI (architectural distortion, suspicious calcifications) that are not accessible by image-guided core biopsy require wire-guided or ROLL (radioguided occult lesion localisation) excision biopsy.

Eligibility for breast-conserving surgery (lumpectomy) versus mastectomy is determined by the multidisciplinary breast team based on:

• Tumour size relative to breast volume: Wide local excision is feasible when adequate surgical margins can be achieved without unacceptable cosmetic deformity. Oncoplastic techniques extend breast-conserving eligibility to T2–T3 tumours in larger-breasted women.
• Tumour location: Central tumours (beneath the nipple) traditionally required mastectomy; nipple-sparing mastectomy or central lumpectomy with nipple reconstruction are now options at specialist centres.
• Multicentricity: Two or more invasive foci in different breast quadrants is generally a contraindication to lumpectomy; total mastectomy is required for multifocal/multicentric disease not amenable to single wide excision.
• Prior breast irradiation: Patients who have previously received whole-breast radiotherapy are not eligible for repeat radiotherapy after lumpectomy — mastectomy is required for recurrence in an irradiated breast.
• BRCA1/2 mutation carriers: Bilateral mastectomy is often recommended due to the substantially elevated lifetime contralateral breast cancer risk (40–87%), though lumpectomy followed by surveillance is an acceptable alternative in fully counselled patients.

Pre-operative workup includes: Bilateral mammography and targeted breast ultrasound, MRI for lobular histology, high-risk patients, or significant size uncertainty; core needle biopsy of the index lesion; sentinel lymph node mapping with radiotracer injection the day before surgery; anaesthetic assessment; and informed consent covering margin assessment, sentinel node biopsy, conversion to mastectomy if margins repeatedly involved, and need for adjuvant radiotherapy.

Excision biopsy: Removal of the entire lump plus a small rim of surrounding tissue for histological diagnosis. Used when core needle biopsy is non-diagnostic or technically not feasible. Performed through a curvilinear incision placed in the direction of Langer's skin tension lines for optimal cosmesis. May be combined with wire-guided localisation or ROLL for non-palpable lesions.

Wire-guided (hookwire) localisation excision: For impalpable lesions, a radiologist inserts a fine wire under mammographic or ultrasound guidance to mark the lesion. The surgeon then excises the tissue bracketing the wire under imaging guidance, confirmed by specimen radiography to verify complete excision. Radio-guided occult lesion localisation (ROLL) and radioactive seed localisation (RSL) are newer alternatives allowing more flexible scheduling and avoiding wire-related patient discomfort during transport.

Wide local excision (lumpectomy): Removal of the tumour with a macroscopic margin of 5–10 mm normal tissue circumferentially, oriented with clips for pathological assessment of six margins. Specimen radiography confirms orientation; cavity shavings may be taken from all six walls to improve margin clearance rates. Intraoperative cavity marking with metal clips guides post-operative radiotherapy boost delivery.

Oncoplastic breast surgery: Integrates lumpectomy with local tissue rearrangement or reduction mammaplasty techniques to reshape the breast after tumour removal, allowing wider excisions and improved cosmesis. Level I oncoplasty (volume displacement) uses local flaps within the breast; Level II (volume replacement) uses myocutaneous flaps (latissimus dorsi mini-flap) or fat grafting to fill the excision cavity. Allows breast-conserving surgery in tumours up to 10 cm in appropriately selected patients.

Vacuum-assisted excision (Mammotome, EnCor): For small benign fibroadenomas and some BI-RADS 3–4 lesions, large-bore vacuum-assisted biopsy devices can excise small (<2 cm) lesions through a single 3–5 mm skin nick under local anaesthesia under ultrasound guidance — essentially scarless outpatient removal.

• Equivalent survival to mastectomy: Twenty-year data from NSABP B-06 and EORTC 10801 confirm that lumpectomy plus radiotherapy for early breast cancer achieves identical overall survival and breast cancer-specific survival as total mastectomy. This equivalence is the cornerstone of breast-conserving surgery practice.
• Preserved breast: Breast conservation preserves body image, avoids the psychological impact of mastectomy, and eliminates the need for breast reconstruction in most patients.
• Shorter operation and recovery: Lumpectomy with SLNB is typically a 1–2 hour day-case procedure; total mastectomy requires 2–5 hours and a 2–5 night admission. Recovery after lumpectomy is 2–3 weeks versus 4–6 weeks for mastectomy.
• Less morbidity: Arm oedema, wound complications, phantom breast sensation, and chest wall numbness are all significantly less frequent after lumpectomy plus SLNB than after mastectomy plus axillary lymph node dissection (ALND).
• Definitive histological diagnosis: Excision biopsy provides the whole lump for histological assessment — advantage over core biopsy in cases with discordant results or where sampling error is suspected.
• Access to adjuvant radiotherapy: Postoperative whole-breast irradiation reduces local recurrence after lumpectomy by approximately 50%, and reduces 15-year breast cancer mortality by approximately 3–4% in absolute terms per the EBCTCG meta-analysis.

• Incomplete excision (positive margins): Tumour at the inked margin occurs in 15–25% of initial lumpectomies, requiring re-excision or mastectomy. Intraoperative techniques (frozen section margin assessment, specimen radiography) and good pre-operative planning reduce re-excision rates.
• Haematoma: Post-operative blood collection in the excision cavity occurs in 2–5%. Small haematomas resolve spontaneously; large haematomas may require aspiration or surgical drainage.
• Seroma: Fluid accumulation in the cavity is common (10–20%) after larger excisions or when the axilla is included; usually resolves with one or two clinic aspirations.
• Wound infection: Superficial wound infections in 2–5%; deep breast abscesses are rare (<1%) with perioperative antibiotic prophylaxis.
• Cosmetic deformity: The excision cavity may leave a visible dimpling, volume deficit, or scar contracture, particularly for larger excisions in smaller breasts, superior pole tumours, or when post-operative radiotherapy causes fibrosis. Oncoplastic planning reduces this risk.
• Lymphoedema: Arm swelling from sentinel lymph node biopsy alone is very rare (<3%); risk increases substantially with full axillary lymph node dissection (15–20% at 5 years). Physiotherapy-guided exercises and compression garments are used for established lymphoedema.
• Numbness and altered sensation: The intercostobrachial nerve, providing sensation to the inner arm, is commonly stretched or divided during axillary surgery, causing numbness, tingling, or hyperaesthesia in the inner upper arm in 50–70% of patients, often permanent.
• Local recurrence: After lumpectomy plus radiotherapy, ipsilateral breast tumour recurrence occurs in approximately 1% per year; 10-year risk 5–10% depending on tumour biology, excision margins, and radiotherapy technique.

Most lumpectomy procedures are performed as day cases with discharge on the same day or after one overnight stay. Wound dressings are reviewed at 5–7 days; drains (if placed) are removed when output falls below 30–50 mL per day. Arm exercises to prevent stiffness and shoulder restriction are commenced immediately post-operatively and continued for 3–6 weeks.

Histological results from the excision specimen are available within 7–14 days (paraffin processing for permanent sections). Results are discussed at a multidisciplinary breast team meeting to determine the need for further surgery (positive margins), adjuvant chemotherapy, hormonal therapy (tamoxifen or aromatase inhibitors for hormone receptor-positive tumours), and radiotherapy planning.

Adjuvant whole-breast radiotherapy typically commences 4–6 weeks after surgery once the wound has healed, delivered as 15–16 fractions over 3 weeks (FAST-Forward hypofractionation protocol, UK standard) or 25 fractions over 5 weeks (conventional fractionation). A radiotherapy boost to the tumour cavity (3–5 additional fractions) is added for patients with high recurrence risk (young age, grade 3 histology, close margins).

Breast cancer follow-up after completing treatment: clinical examination every 6 months for 2 years, then annually; annual bilateral mammography for the first 5 years, then according to local protocol. Hormone therapy (tamoxifen for premenopausal women, aromatase inhibitors for postmenopausal) is taken for 5–10 years and requires annual monitoring.

Breast lump surgery costs vary substantially by procedure complexity, hospital grade, and country. Medical tourism for breast cancer surgery is feasible for elective cases where timing is not immediately critical.

In India, lumpectomy with SLNB at JCI or NABH-accredited breast oncology centres costs USD 800–2,500 including surgeon, anaesthetist, operating room, and 1-night admission. Comprehensive packages including pre-operative staging (MRI, bone scan), surgery, and post-operative histology reporting cost USD 1,500–4,000. Major centres with dedicated breast units include Tata Memorial Hospital (Mumbai), Apollo Hospitals (nationwide), Fortis Healthcare, and Manipal Hospitals. Adjuvant radiotherapy at these centres costs USD 2,000–5,000 for a full course.

Thailand: lumpectomy USD 3,000–7,000 at Bangkok's international hospitals (Bumrungrad, Samitivej, Bangkok Hospital). Turkey: USD 2,000–6,000 at JCI-accredited centres in Istanbul. Singapore: USD 8,000–20,000 — premium oncology care at National University Hospital, Mount Elizabeth, and Gleneagles.

In the United States, lumpectomy with SLNB costs USD 8,000–25,000; with complications or same-day breast reconstruction USD 20,000–50,000. Insurance coverage is mandatory for breast cancer treatment under the ACA; out-of-pocket maximums apply. UK NHS provides all breast cancer treatment free of charge on clinical need; private breast surgery costs GBP 5,000–15,000. Patients travelling for breast cancer surgery should allow 4–6 weeks stay to include pre-operative assessment, surgery, wound review, and histology review before returning home for adjuvant treatment.

For confirmed malignancy: mastectomy (total breast removal) is the alternative to lumpectomy when breast-conserving surgery is not feasible — very large tumours relative to breast size, multicentric disease, prior irradiation, or patient preference. Skin-sparing and nipple-sparing mastectomy with immediate reconstruction (tissue expander, implant, or autologous flap) achieves excellent cosmetic outcomes and equivalent oncological safety.

For benign lumps: observation with 6-monthly ultrasound surveillance is appropriate for confirmed fibroadenomas BI-RADS 2–3 classified as stable on biopsy. Non-surgical ablation techniques including cryoablation (Cryoablation for Fibroadenoma — CSF-01 trial), high-intensity focused ultrasound (HIFU), and radiofrequency ablation are being evaluated for fibroadenoma treatment with growing evidence for efficacy in small lesions.

For non-palpable lesions: vacuum-assisted stereotactic biopsy (Mammotome VAB) can completely excise small (<15 mm) suspicious lesions such as clusters of calcifications, potentially serving as both diagnostic and therapeutic intervention if histology confirms benign diagnosis and the entire lesion is removed. For DCIS: emerging evidence supports primary endocrine therapy (aromatase inhibitor) as an alternative to surgery in elderly or frail patients with low-grade ER-positive DCIS — under evaluation in LORD, LORIS, COMET, and IDENTITY trials.